Related Experiment Videos
Isradipine in essential hypertension: the Belgian General Practitioners' Study
P De Keyser1, J Bouvé, D Clement
1Department of Clinical Research, Sandoz Belgium, Brussels.
The American Journal of Medicine
|April 17, 1989
Summary
Isradipine effectively lowers blood pressure in hypertensive patients, alone or with guanfacine. This combination therapy achieved normotension in 67.6% of participants within 12 weeks.
Area of Science:
- Cardiology
- Pharmacology
- General Practice
Background:
- Hypertension is a prevalent cardiovascular risk factor requiring effective management.
- Isradipine and guanfacine are established antihypertensive agents.
Purpose of the Study:
- To evaluate the efficacy, tolerability, and safety of isradipine monotherapy and its combination with guanfacine in hypertensive patients.
- To determine the percentage of patients achieving normotension with the studied treatments.
Main Methods:
- A 12-week, single-blind study involving 212 hypertensive patients across 37 general practices.
- Patients received isradipine (1.25-2.5 mg BID), with 30% later adding guanfacine (1 mg daily).
- Blood pressure, side effects, ECGs, and lab tests were monitored.
Main Results:
- Isradipine monotherapy reduced diastolic blood pressure to ≤90 mm Hg in 52.6% of patients.
- Combination therapy with guanfacine resulted in normotension in 67.6% of patients by Week 12.
- Increased incidence of flushing and edema with isradipine; dry mouth with added guanfacine. No significant adverse ECG or lab findings.
Conclusions:
- Isradipine, as monotherapy or combined with guanfacine, is an effective antihypertensive treatment.
- The combination therapy demonstrated a higher rate of achieving normotension.
- Further long-term follow-up is planned to assess sustained efficacy and safety.